A Study to Evaluate Rapid Throughput Screening for Human COVID-19 Infection
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Elie F Berbari, MD
Mayo Clinic
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Sri Jayadeva
Bengaluru, Karnataka, India
- King Edward Memorial Hospital
Mumbai, Maharashtra, India
- Gregorio Marañon Hospital
Madrid, Spain
- Imperial College
London, England, United Kingdom
- Mayo Clinic
Phoenix, Arizona, United States
- Mayo Clinic
Jacksonville, Florida, United States
- Lsuhsc Shreveport
Shreveport, Louisiana, United States
- Henry Ford Health System
West Bloomfield, Michigan, United States
- Mayo Clinic
Rochester, Minnesota, United States
- Hackensack Meridian Health
Hackensack, New Jersey, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 10 Dec 2020
- Primary completion
- 3 Jun 2021
- Completion
- 3 Jun 2021
- Last update posted
- 9 Sept 2021
- Registered enrollment
- 2,821
- Registry id
- NCT04725097
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.